The global mTOR inhibitors market is expected to grow at a CAGR of 7.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing prevalence of cancer and kidney transplantation, which are major indications for mTOR inhibitors. Rapamune (sirolimus) is the most commonly prescribed drug in this category and accounted for over 50% share in 2017. Torisel (temsirolimus) was launched in 2009 and has been approved by FDA as a treatment for renal cell carcinoma (RCC). Afinitor (everolimus) was launched in 2011 and has been approved by FDA as a treatment for advanced RCC that cannot be treated with surgery or radiation therapy alone. Zortress (givinostat), which was launched in 2013, has been approved by FDA as an adjunct to chemotherapy for patients with metastatic colorectal cancer who have not received prior chemotherapy or who have progressed on prior chemotherapy.
Some Of The Growth Factors Of This Market:
- Increasing awareness about the benefits of mTOR inhibitors for treating various cancers will also drive the growth of this market during the forecast period from 2018-2025.
- In addition, increasing research on novel targets for drug discovery will also fuel the growth of this market during the forecast period from 2018-2025 .
Industry Growth Insights published a new data on “mTOR Inhibitors Market”. The research report is titled “mTOR Inhibitors Market research by Types (Rapamune, Torisel, Afinitor, Zortress), By Applications (Tumor Treatment, Kidney Transplant, Others), By Players/Companies LC Laboratories, Teva Pharmaceutical Industries Ltd., Exelixis, Novartis Oncology, Pfizer, GSK”.
Scope Of The Report
Report Attributes
Report Details
Report Title
mTOR Inhibitors Market Research Report
By Type
Rapamune, Torisel, Afinitor, Zortress
By Application
Tumor Treatment, Kidney Transplant, Others
By Companies
LC Laboratories, Teva Pharmaceutical Industries Ltd., Exelixis, Novartis Oncology, Pfizer, GSK
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global mTOR Inhibitors Market Report Segments:
The global mTOR Inhibitors market is segmented on the basis of:
Types
Rapamune, Torisel, Afinitor, Zortress
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumor Treatment, Kidney Transplant, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- LC Laboratories
- Teva Pharmaceutical Industries Ltd.
- Exelixis
- Novartis Oncology
- Pfizer
- GSK
Highlights of The mTOR Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rapamune
- Torisel
- Afinitor
- Zortress
- By Application:
- Tumor Treatment
- Kidney Transplant
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the mTOR Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
mTOR inhibitors are drugs that block the activity of mTOR, a protein that is important in the growth and maintenance of cells. TOR inhibitors can help to prevent or delay the progression of cancer by slowing down the growth and spread of tumors.
Some of the key players operating in the mtor inhibitors market are LC Laboratories, Teva Pharmaceutical Industries Ltd., Exelixis, Novartis Oncology, Pfizer, GSK.
The mtor inhibitors market is expected to register a CAGR of 7.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. mTOR Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. mTOR Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. mTOR Inhibitors Market - Supply Chain
4.5. Global mTOR Inhibitors Market Forecast
4.5.1. mTOR Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. mTOR Inhibitors Market Size (000 Units) and Y-o-Y Growth
4.5.3. mTOR Inhibitors Market Absolute $ Opportunity
5. Global mTOR Inhibitors Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. mTOR Inhibitors Market Size and Volume Forecast by Type
5.3.1. Rapamune
5.3.2. Torisel
5.3.3. Afinitor
5.3.4. Zortress
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global mTOR Inhibitors Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. mTOR Inhibitors Market Size and Volume Forecast by Application
6.3.1. Tumor Treatment
6.3.2. Kidney Transplant
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global mTOR Inhibitors Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. mTOR Inhibitors Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global mTOR Inhibitors Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. mTOR Inhibitors Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global mTOR Inhibitors Demand Share Forecast, 2019-2026
9. North America mTOR Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America mTOR Inhibitors Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America mTOR Inhibitors Market Size and Volume Forecast by Application
9.4.1. Tumor Treatment
9.4.2. Kidney Transplant
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America mTOR Inhibitors Market Size and Volume Forecast by Type
9.7.1. Rapamune
9.7.2. Torisel
9.7.3. Afinitor
9.7.4. Zortress
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America mTOR Inhibitors Demand Share Forecast, 2019-2026
10. Latin America mTOR Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America mTOR Inhibitors Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America mTOR Inhibitors Market Size and Volume Forecast by Application
10.4.1. Tumor Treatment
10.4.2. Kidney Transplant
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America mTOR Inhibitors Market Size and Volume Forecast by Type
10.7.1. Rapamune
10.7.2. Torisel
10.7.3. Afinitor
10.7.4. Zortress
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America mTOR Inhibitors Demand Share Forecast, 2019-2026
11. Europe mTOR Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe mTOR Inhibitors Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe mTOR Inhibitors Market Size and Volume Forecast by Application
11.4.1. Tumor Treatment
11.4.2. Kidney Transplant
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe mTOR Inhibitors Market Size and Volume Forecast by Type
11.7.1. Rapamune
11.7.2. Torisel
11.7.3. Afinitor
11.7.4. Zortress
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe mTOR Inhibitors Demand Share, 2019-2026
12. Asia Pacific mTOR Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific mTOR Inhibitors Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific mTOR Inhibitors Market Size and Volume Forecast by Application
12.4.1. Tumor Treatment
12.4.2. Kidney Transplant
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific mTOR Inhibitors Market Size and Volume Forecast by Type
12.7.1. Rapamune
12.7.2. Torisel
12.7.3. Afinitor
12.7.4. Zortress
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific mTOR Inhibitors Demand Share, 2019-2026
13. Middle East & Africa mTOR Inhibitors Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa mTOR Inhibitors Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa mTOR Inhibitors Market Size and Volume Forecast by Application
13.4.1. Tumor Treatment
13.4.2. Kidney Transplant
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa mTOR Inhibitors Market Size and Volume Forecast by Type
13.7.1. Rapamune
13.7.2. Torisel
13.7.3. Afinitor
13.7.4. Zortress
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa mTOR Inhibitors Demand Share, 2019-2026
14. Competition Landscape
14.1. Global mTOR Inhibitors Market: Market Share Analysis
14.2. mTOR Inhibitors Distributors and Customers
14.3. mTOR Inhibitors Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. LC Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Teva Pharmaceutical Industries Ltd.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Exelixis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis Oncology
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GSK
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook